By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BerGenBio AS 

Thormohlensgt 51, 5006

  Bergen    Norway
Phone: 47-535-01-564 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
BerGenBio AS Invitation To Second Quarter And Half Year 2017 Results Presentation And Webcast 8/11/2017 8:13:37 AM
BerGenBio AS To Present Its First-In-Class, Selective AXL Inhibitor BGB324 At Precision: Lung Cancer - World R&D Summit In Boston 7/26/2017 10:56:16 AM
BerGenBio AS Awarded NOK 24 Million From Innovasjon Norge To Support The Clinical Development Of BGB324 In Combination With KEYTRUDA For Advanced Lung Cancer 6/26/2017 8:05:29 AM
BerGenBio AS’s Selective First-In-Class Axl Inhibitor, BGB324, Featured In A Poster Presentation At ASCO Annual Meeting 2017 6/6/2017 1:49:41 PM
BerGenBio AS: Results For The First Quarter 2017 5/23/2017 12:03:15 PM
BerGenBio AS Announces Start Of Randomized Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 In Combination With Current Therapies In Melanoma 5/22/2017 11:36:35 AM
Abstract Showing Activity In MDS Of BerGenBio AS’s First-In-Class AXL Inhibitor, BGB324, Accepted For Presentation At ASCO Annual Meeting 2017 5/19/2017 9:24:06 AM
BerGenBio AS Enters Collaboration With Merck & Co. (MRK) Focused On Clinical Evaluation Of BGB324 In Combination With KEYTRUDA (Pembrolizumab) In Advanced Lung And Breast Cancer 3/8/2017 9:00:19 AM
BerGenBio AS Release: New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance 12/8/2016 10:45:52 AM
BerGenBio AS Release: New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance 12/8/2016 9:18:57 AM
12345
//-->